Melanotan-associated transverse melanonychia

[en] Transverse melanonychia has multiple causes, but is principally observed as adverse effect to drug intake, such as minocyclin, zidovudine and chemotherapies, like pemetrexed,VAD (vincristine, adriamycin and dexamathasone) and hydroxyurea. Other causes include radiation therapy and electron beam therapy.

Disciplines :

Dermatology

Author, co-author :

PAUROBALLY, Dilshad ; Centre Hospitalier Régionale de la Citadelle (Liège) - CHR CITADELLE > dermatologie

EL HAYDERI, Lara ; Centre Hospitalier Universitaire de Liège - CHU > Dermatologie

Richert, Bernard; Centre Hospitalier Universitaire Saint-Pierre (Bruxelles) - CHU St-Pierre > Dermatology

Andre, Josette

NIKKELS, Arjen ; Centre Hospitalier Universitaire de Liège - CHU > Dermatologie

Language :

English

Title :

Melanotan-associated transverse melanonychia

Publication date :

2013

Journal title :

Journal of the European Academy of Dermatology and Venereology

ISSN :

0926-9959

eISSN :

1468-3083

Publisher :

Blackwell Publishing, Oxford, United Kingdom

Volume :

Pages :

124-130

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 09 November 2015

Statistics

Number of views

123 (1 by ULiège)

Number of downloads

2 (2 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Tosti A, Baran R, Dawber RPR,. The nail in sytemic diseases and drug-induced changes. In, Baran R, Dawber RPR, de Berker DAR, Haneke E, Tosti A, eds. Diseaes of the Nails and Their Management, 3rd edn. Blackwell Scientific Publications, Oxford, 2001: 223-329.
Dasanu CA, Wiernik PH, Vaillant J, Alexandrescu DT,. A complex pattern of melanonychia and onycholysis after treatment with pemetrexed for lung cancer. Skinmed 2007; 6: 95-96.
Dasanu CA, Vaillant JG, Alexandrescu DT,. Distinct patterns of chromonychia, Beau's lines, and melanoderma seen with vincristine, adriamycin, dexamethasone therapy for multiple myeloma. Dermatol Online J 2006; 12: 10.
Teo RY, Tan E,. A case of hydroxyurea-induced transverse melanonychia. Int J Dermatol 2006; 45: 1329-1330.
Lang K, Groeger M, Neumann NJ, Ruzicka T, Fritsch C,. Supravenous hyperpigmentation, transverse leuconychia and transverse melanonychia after chemotherapy for Hodgkin's disease. J Eur Acad Dermatol Venereol 2002; 16: 162-163.
Pellicane BL, Rashid RM,. Transverse melanonychia after radiation therapy. Cutis 2010; 85: 239-241.
Quinlan KE, Janiga JJ, Baran R, Lim W,. Transverse melanonychia secondary to total skin electron beam therapy: a report of 3 cases. J Am Acad Dermatol 2005; 53: S112-S114.
Langan EA, Nie Z, Rhodes LE,. Melanotropic peptides: more than just 'Barbie drugs' and 'sun-tan jabs'? Br J Dermatol 2010; 163: 451-455.
Cousen P, Colver G, Helbling I,. Eruptive melanocytic naevi following melanotan injection. Br J Dermatol 2009; 161: 707-708.
Cardones AR, Grichnik JM,. alpha-Melanocyte-stimulating hormone-induced eruptive nevi. Arch Dermatol 2009; 145: 441-444.
Ellis R, Kirkham N, Seukeran D,. Malignant melanoma in a user of melanotan I. Br Med J 2009. http://www.bmj.com/cgi/eletters/338/feb17-2/ b566#209418.
Paurobally D, Jason F, Dezfoulian B, Nikkels AF,. Melanotan-associated melanoma. Br J Dermatol 2011; 163: 1403-1405.